-
Sector Analysis
Alzheimer’s Disease in 68 Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβmonoclonal antibodies (mAbs) across the 8MM.he US and China markets make up the majority of total global sales, contributing $1.1 billion (44.7%) and $915.2...
-
Sector Analysis
Alzheimer’s Disease: Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2033
This report covers the 8 major markets and provides an Excel-based forecast model for the Alzheimer’s Disease market through 2033. GlobalData estimates that the value of the Alzheimer’s Disease (AD) market in the 8MM in 2023 was $2.4 billion. This market is defined as sales of symptamatic and disease modifying (DMT) treatments including including approval of anti-Aβ monoclonal antibodies (mAbs) across the 8MM (US, France, Germany, Italy, Spain, UK, Japan and China). The US and China markets make up the...
-
Product Insights
Alzheimer's Disease: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Alzheimer's Disease - Global Clinical Trials Review, 2026" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Barriers for Leqembi and Kisunla in Seeking Reimbursement for Treating Alzheimer's Disease
GlobalData analyses of global regulatory and reimbursement progress indicate that the commercial launches of Leqembi (lecanemab) and Kisunla (donanemab) create a high-stakes test of whether disease-modifying therapies with contested long-term clinical value and safety concerns can nonetheless achieve market access in major markets.
-
Sector Analysis
Alzheimer’s Disease (AD) Epidemiology Analysis and Forecast to 2033
Alzheimer’s Disease (AD) Report Overview In the 8MM, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in 2023. The total prevalent cases of AD will register an AGR of more than 4% during 2023-2033. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. It is typically characterized by memory loss, cognitive impairment, functional decline, and gradual inability in performing daily tasks independently. Although the exact...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.